Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial
Asadirad et al.,
Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of..,
Phytotherapy Research, doi:10.1002/ptr.7375
RCT 60 hospitalized patients in Iran, 30 treated with nano-curcumin, showing significant improvements in inflammatory cytokines, and improvements in clinical outcomes without statistical significance. 240 mg/day nano-curcumin for 7 days.
risk of death, 25.9% lower, RR 0.74, p = 0.74, treatment 5 of 27 (18.5%), control 6 of 24 (25.0%), NNT 15, excluding patients that stopped treatment due to progression - 3 for curcumin and 6 for control.
|
risk of progression, 50.0% lower, RR 0.50, p = 0.47, treatment 3 of 30 (10.0%), control 6 of 30 (20.0%), NNT 10.0.
|
risk of unresolved fever, 45.3% lower, RR 0.55, p = 0.09, treatment 8 of 27 (29.6%), control 13 of 24 (54.2%), NNT 4.1.
|
risk of unresolved dyspnea, 28.9% lower, RR 0.71, p = 0.72, treatment 4 of 27 (14.8%), control 5 of 24 (20.8%), NNT 17.
|
risk of unresolved cough, 40.7% lower, RR 0.59, p = 0.36, treatment 6 of 27 (22.2%), control 9 of 24 (37.5%), NNT 6.5.
|
risk of O2 <92%, 36.5% lower, RR 0.63, p = 0.51, treatment 5 of 27 (18.5%), control 7 of 24 (29.2%), NNT 9.4.
|
risk of O2 <97%, 20.0% lower, RR 0.80, p = 0.21, treatment 18 of 27 (66.7%), control 20 of 24 (83.3%), NNT 6.0.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Asadirad et al., 17 Jan 2022, Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 7 authors.
Abstract: Received: 14 July 2021
Revised: 11 December 2021
Accepted: 22 December 2021
DOI: 10.1002/ptr.7375
RESEARCH ARTICLE
Antiinflammatory potential of nano-curcumin as an alternative
therapeutic agent for the treatment of mild-to-moderate
hospitalized COVID-19 patients in a placebo-controlled clinical
trial
Ali Asadirad1,2
| Roohangiz Nashibi3 | Ali Khodadadi1,2
Mahvash Sadeghi1,4 | Azam Aminian2,5 | Sajad Dehnavi1
1
Department of Immunology, School of
Medicine, Ahvaz Jundishapur University of
Medical Sciences, Ahvaz, Iran
| Ata A Ghadiri1 |
Abstract
The present study conducted a placebo-controlled clinical trial to evaluate the impact of
2
Cancer, Petroleum and Environmental
Pollutants Research Center, Ahvaz
Jundishapur University of Medical Sciences,
Ahvaz, Iran
3
Infectious and Tropical Diseases Research
Center, Health Research Institute, Ahvaz
Jundishapur University of Medical Sciences,
Ahvaz, Iran
4
Student Research Committee, Ahvaz
Jundishapur University of Medical Sciences,
Ahvaz, Iran
5
Department of Nursing, School of Nursing
and Midwifery, Ilam University of Medical
Sciences, Ilam, Iran
Correspondence
Sajad Dehnavi, Department of Immunology,
School of Medicine, Ahvaz Jundishapur
University of Medical Sciences, Ahvaz, Iran.
Email: sjd72dehnavi@gmail.com
Funding information
Ahvaz Jundishapur University of Medical
Sciences, Ahvaz, Iran, Grant/Award Number:
U-99051
1
|
nano-curcumin on the inflammatory cytokines in mild-to-moderate hospitalized COVID19 patients. A total of 60 COVID-19 patients were randomly divided into nano-curcumin
and control groups, and then they received 240 mg/day nano-curcumin for 7 days. The
clinical manifestation and laboratory parameters in patients were recorded on days 0 and
seven. Also, SYBR Green real-time PCR and ELISA techniques were implicated in assessing
the mRNA expression of IFN-γ, IL-1β, IL-6, MCP-1, and TNF-α and the serum levels of IL1β, IL-6, and TNF-α inflammatory mediators, respectively. Although the clinical manifestations and laboratory parameters improved via the nano-curcumin treatment, the mRNA
expression of IFN-γ (p = 0.006) and TNF-α (p = 0.04) were significantly reduced. Besides,
a considerable difference was observed between the nano-curcumin and control groups in
the expression of IFN-γ (p = 0.001), IL-1β (p = 0.0002), and IL-6 (p = 0.008). In addition,
there was a significant difference between the nano-curcumin and control groups in the
serum levels of IL-1β (p = 0.042). The evidence demonstrated that nano-curcumin could
be implicated as a complementary medication to act as an antiinflammatory agent and
inhibit inflammatory complications.
KEYWORDS
coronavirus disease-2019, curcumin, cytokine storm, inflammatory cytokines, severe acute
respiratory syndrome-coronavirus-2
I N T RO DU CT I O N
throat, fatigue, headache, nasal congestion, and gastrointestinal complications (G. Li et al., 2020). Also, some symptoms such as hypoxia,
Coronavirus disease-2019 (COVID-19) is a newly emerged respiratory
dyspnea, and difficulty breathing may be observed in patients with
viral disease caused by the new coronavirus 2019 (2019-nCoV). This
severe forms. This situation requires intensive care and mechanical
new virus is also called severe acute respiratory syndrome-
ventilation. Approximately 15% of patients progress to acute pneumo-
coronavirus-2 (SARS-CoV-2). COVID-19 is characterized as a pan-
nia, and in 5% of cases, this disease is accompanied by the acute..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit